Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Bioventus (BVS) EBT (2020 - 2025)

Bioventus' EBT history spans 6 years, with the latest figure at $14.1 million for Q4 2025.

  • For Q4 2025, EBT rose 26784.91% year-over-year to $14.1 million; the TTM value through Dec 2025 reached $25.7 million, up 149.12%, while the annual FY2025 figure was $25.7 million, 149.12% up from the prior year.
  • EBT reached $14.1 million in Q4 2025 per BVS's latest filing, up from $4.7 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $24.5 million in Q2 2021 to a low of -$130.6 million in Q4 2022.
  • Average EBT over 5 years is -$16.4 million, with a median of -$5.4 million recorded in 2024.
  • Peak YoY movement for EBT: plummeted 4043.38% in 2022, then soared 26784.91% in 2025.
  • A 5-year view of EBT shows it stood at -$2.8 million in 2021, then crashed by 1079.64% to -$32.4 million in 2022, then skyrocketed by 74.09% to -$8.4 million in 2023, then soared by 99.37% to -$53000.0 in 2024, then skyrocketed by 26784.91% to $14.1 million in 2025.
  • Per Business Quant, the three most recent readings for BVS's EBT are $14.1 million (Q4 2025), $4.7 million (Q3 2025), and $10.3 million (Q2 2025).